Barcelona, Spain : 28 - 29 May 2018
Foyer of VHIO
Session 1 - LIF in cancer I
Chair: Joan Seoane
Joan Seoane VHIO, Spain
"Immunomodulatory role of LIF in cancer"
Cédric Gaggioli IRCAN, France
"A journey into the tumor microenvironment: a LIF(e) story"
Wenwei Hu Rutgers Cancer Institute, USA
"LIF, a Friend or Foe – its role in reproduction and cancer"
Session 2 - Early phase clinical trials
José Baselga MSKCC, USA
"Update on clinical development of anti-LIF antibodies as cancer therapy"
Lillian Siu University of Toronto, Canada
"Incorporating predictive biomarker development in first-in-class phase I trials – myth or must?"
Josep Tabernero VHIO, Spain
Title to be announced
Bus to Evening Reception
All participants are invited to join this social event. Drinks and hors d'oeuvres will be served in the garden of the hotel. The event will finish at 20:30, and the rest of the evening is free for you to enjoy Barcelona.
Session 3 - LIF in cancer II
Chair: Tony Hunter
Tony Hunter Salk Institute, USA
"The role of the LIF stem cell factor in pancreatic cancer"
Benjamin Neel NYU School of Medicine, USA
"Targeting SHP2 in Cancer"
Peter Heinrich Albert-Ludwig University, Germany
"Molecular mechanism of IL-6-type-cytokine signalling through the gp130- JAK- STAT pathway and its regulation"
Andrew Lowy UCSD, USA
"Identifying novel therapeutic targets for pancreatic cancer therapy"
Manuel Serrano IRB Barcelona, Spain
"Requirement of IL-6 for reprogramming of somatic cells into embryonic pluripotency"
Session 4 - LIF in inflammation
Chair: Su Metcalfe
Su Metcalfe University of Cambridge, UK
"LIF formulated as targeted LIFNano particles as a therapeutic"
Niels Hellings Hasselt University, Belgium
"IL-6 Class Cytokines are Master Regulators of Neuroimmunological Disease"
Keith Pennypacker University of Kentucky, USA
"Age-related differences in the response to Leukemia Inhibitory Factor after experimental stroke"
Session 5 - Drug development
Chair: Su Metcalfe
Jeanne Magram Northern Biologics, Canada
"Targeting LIF: MSC-1 as a novel cancer immunotherapy"